Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Despite significant progress in the development of therapies for relapsing MS, progressive MS remains comparatively disappointing. Our objective, in this paper, is to review the current challenges in developing therapies for progressive MS and identify key priority areas for research. A collaborative was convened by volunteer and staff leaders from several MS societies with the mission to expedite the development of effective disease-modifying and symptom management therapies for progressive forms of multiple sclerosis. Through a series of scientific and strategic planning meetings, the collaborative identified and developed new perspectives on five key priority areas for research: experimental models, identification and validation of targets and repurposing opportunities, proof-of-concept clinical trial strategies, clinical outcome measures, and symptom management and rehabilitation. Our conclusions, tackling the impediments in developing therapies for progressive MS will require an integrated, multi-disciplinary approach to enable effective translation of research into therapies for progressive MS. Engagement of the MS research community through an international effort is needed to address and fund these research priorities with the ultimate goal of expediting the development of disease-modifying and symptom-relief treatments for progressive MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2 (2011) · Nature · doi:10.1038/nature10251 · Cited by 2,697 · cited 1×
“Multiple Sclerosis Journal 18(11) 1534 –1540 © The Author(s) 2012 Reprints and permissions: sagepub.”
BackgroundRisk Alleles for Multiple Sclerosis Identified by a Genomewide Study
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa073493 · Cited by 1,746
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
Drug target identification using side-effect similarity
Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P. (2008) · Science · doi:10.1126/science.1158140 · Cited by 1,248
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Self-citationAnxiety disorders and their clinical correlates in multiple sclerosis patients
Korostil, M., & Feinstein, A. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458506071161 · Cited by 424
Self-citationMohr, D. C., Boudewyn, A. C., Goodkin, D. E., Bostrom, A., & Epstein, L. (2001) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.69.6.942 · Cited by 334
Cohen, J. A., Reingold, S. C., Polman, C. H., & Wolinsky, J. S. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70059-5 · Cited by 233
Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis
Ehde, D. M., Kraft, G. H., Chwastiak, L., Sullivan, M. D., Gibbons, L. E., Bombardier, C. H., & Wadhwani, R. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.08.002 · Cited by 107
Experimental models of multiple sclerosis
Pachner, A. R. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328346c226 · Cited by 90
Cited by
Reich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1401483 · Cited by 2,491
Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity
Browne, P., Chandraratna, D., Angood, C., Tremlett, H., Baker, C., Taylor, B. V., & Thompson, A. J. (2014) · Neurology · doi:10.1212/wnl.0000000000000768 · Cited by 1,223
Self-citationInefficient clearance of myelin debris by microglia impairs remyelinating processes
Lampron, A., Larochelle, A., Laflamme, N., Préfontaine, P., Plante, M.-M., Sánchez, M. G., Yong, V. W., Stys, P. K., Tremblay, M.-È., & Rivest, S. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141656 · Cited by 595
Molnarfi, N., Schulze-Topphoff, U., Weber, M. S., Patarroyo, J. C., Prod’homme, T., Varrin-Doyer, M., Shetty, A., Linington, C., Slavin, A. J., Hidalgo, J., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130699 · Cited by 418
Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function
Ontaneda, D., Thompson, A. J., Fox, R. J., & Cohen, J. A. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31320-4 · Cited by 298
Self-citation
Metadata
- Authors
- Fox, R. J., Thompson, A., Baker, D., Baneke, P., Brown, D., Browne, P., Chandraratna, D., Ciccarelli, O., Coetzee, T., Comi, G., Feinstein, A., Kapoor, R., Lee, K., Salvetti, M., Sharrock, K., Toosy, A., Zaratin, P., & Zuidwijk, K.
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2012-08-23
- Volume
- 18
- Issue
- 11
- Pages
- 1534-1540
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W2171821866
- Cited by
- 117
- References
- 10
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS. https://app.cochat.ai/papers/10.1177/1352458512458169
- The paper
- Fox, R. J., Thompson, A., Baker, D., Baneke, P., Brown, D., Browne, P., Chandraratna, D., Ciccarelli, O., Coetzee, T., Comi, G., Feinstein, A., Kapoor, R., Lee, K., Salvetti, M., Sharrock, K., Toosy, A., Zaratin, P., & Zuidwijk, K. (2012). Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458512458169
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.